Literature DB >> 30121138

Decreased Cannabinoid CB1 Receptors in Male Tobacco Smokers Examined With Positron Emission Tomography.

Jussi Hirvonen1, Paolo Zanotti-Fregonara2, David A Gorelick3, Chul Hyoung Lyoo4, Denise Rallis-Frutos4, Cheryl Morse4, Sami S Zoghbi4, Victor W Pike4, Nora D Volkow5, Marilyn A Huestis6, Robert B Innis4.   

Abstract

BACKGROUND: Previous studies showed reduction of brain cannabinoid CB1 receptors in adults with cannabis and alcohol use disorders. Preclinical data suggest that these receptors also contribute to nicotine reward and dependence. Tobacco smoking may confound clinical studies of psychiatric disorders because many patients with such disorders smoke tobacco. Whether human subjects who smoke tobacco but are otherwise healthy have altered CB1 receptor binding in brain is unknown.
METHODS: We measured CB1 receptors in brains of 18 healthy men who smoke tobacco (frequent chronic cigarette smokers), and 28 healthy men who do not smoke tobacco, using positron emission tomography and [18F]FMPEP-d2, a radioligand for CB1 receptors. We collected arterial blood samples during scanning to calculate the distribution volume (VT), which is nearly proportional to CB1 receptor density. Repeated-measures analysis of variance compared VT between groups in various brain regions.
RESULTS: Brain CB1 receptor VT was about 20% lower in subjects who smoke tobacco than in subjects who do not. Decreased VT was found in all brain regions, but reduction did not correlate with years of smoking, number of cigarettes smoked per day, or measures of nicotine dependence.
CONCLUSIONS: Tobacco-smoking healthy men have a widespread reduction of CB1 receptor density in brain. Reduction of CB1 receptors appears to be a common feature of substance use disorders. Future clinical studies on the CB1 receptor should control for tobacco smoking.
Copyright © 2018 Society of Biological Psychiatry. All rights reserved.

Entities:  

Keywords:  Addiction; Brain imaging; Cannabinoid CB(1) receptor; Positron emission tomography; Smoking; Tobacco

Mesh:

Substances:

Year:  2018        PMID: 30121138      PMCID: PMC6388688          DOI: 10.1016/j.biopsych.2018.07.009

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  30 in total

1.  Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain.

Authors:  N Tzourio-Mazoyer; B Landeau; D Papathanassiou; F Crivello; O Etard; N Delcroix; B Mazoyer; M Joliot
Journal:  Neuroimage       Date:  2002-01       Impact factor: 6.556

2.  Reduced cannabinoid CB1 receptor binding in alcohol dependence measured with positron emission tomography.

Authors:  J Hirvonen; P Zanotti-Fregonara; J C Umhau; D T George; D Rallis-Frutos; C H Lyoo; C-T Li; C S Hines; H Sun; G E Terry; C Morse; S S Zoghbi; V W Pike; R B Innis; M Heilig
Journal:  Mol Psychiatry       Date:  2012-07-10       Impact factor: 15.992

3.  Polydrug use in an inpatient treatment sample of problem drinkers.

Authors:  C S Martin; P R Clifford; S A Maisto; M Earleywine; L Kirisci; R Longabaugh
Journal:  Alcohol Clin Exp Res       Date:  1996-05       Impact factor: 3.455

4.  Pooled analysis of three randomized, double-blind, placebo controlled trials with rimonabant for smoking cessation.

Authors:  Jason D Robinson; Paul M Cinciripini; Maher Karam-Hage; Henri-Jean Aubin; Lowell C Dale; Raymond Niaura; Robert M Anthenelli
Journal:  Addict Biol       Date:  2017-04-21       Impact factor: 4.280

5.  In vivo imaging of the cannabinoid CB1 receptor with positron emission tomography.

Authors:  J Hirvonen
Journal:  Clin Pharmacol Ther       Date:  2015-04-17       Impact factor: 6.875

6.  The volitional nature of nicotine exposure alters anandamide and oleoylethanolamide levels in the ventral tegmental area.

Authors:  Matthew W Buczynski; Ilham Y Polis; Loren H Parsons
Journal:  Neuropsychopharmacology       Date:  2012-11-21       Impact factor: 7.853

7.  Positron emission tomography imaging using an inverse agonist radioligand to assess cannabinoid CB1 receptors in rodents.

Authors:  Garth Terry; Jeih-San Liow; Eyassu Chernet; Sami S Zoghbi; Lee Phebus; Christian C Felder; Johannes Tauscher; John M Schaus; Victor W Pike; Christer Halldin; Robert B Innis
Journal:  Neuroimage       Date:  2008-03-18       Impact factor: 6.556

8.  PET imaging of the dopamine transporter with 18F-FECNT: a polar radiometabolite confounds brain radioligand measurements.

Authors:  Sami S Zoghbi; H Umesha Shetty; Masanori Ichise; Masahiro Fujita; Masao Imaizumi; Jeih-San Liow; Jay Shah; John L Musachio; Victor W Pike; Robert B Innis
Journal:  J Nucl Med       Date:  2006-03       Impact factor: 10.057

9.  Delta9-tetrahydrocannabinol decreases somatic and motivational manifestations of nicotine withdrawal in mice.

Authors:  Graciela N Balerio; Ester Aso; Fernando Berrendero; Patricia Murtra; Rafael Maldonado
Journal:  Eur J Neurosci       Date:  2004-11       Impact factor: 3.386

Review 10.  Role of the endogenous cannabinoid system in nicotine addiction: novel insights.

Authors:  Islam Hany Gamaleddin; Jose M Trigo; Aliou B Gueye; Alexander Zvonok; Alexandros Makriyannis; Steven R Goldberg; Bernard Le Foll
Journal:  Front Psychiatry       Date:  2015-03-25       Impact factor: 4.157

View more
  9 in total

Review 1.  Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders.

Authors:  Daniela Navarro; Ani Gasparyan; Francisco Navarrete; Abraham B Torregrosa; Gabriel Rubio; Marta Marín-Mayor; Gabriela B Acosta; Maria Salud Garcia-Gutiérrez; Jorge Manzanares
Journal:  Int J Mol Sci       Date:  2022-04-26       Impact factor: 6.208

2.  The Importance of Drug and Sex Effects in Psychiatric Research.

Authors:  Ansel T Hillmer
Journal:  Biol Psychiatry       Date:  2018-11-15       Impact factor: 13.382

3.  Brain imaging of cannabinoid type I (CB1 ) receptors in women with cannabis use disorder and male and female healthy controls.

Authors:  Tory R Spindle; Hiroto Kuwabara; Alisha Eversole; Ayon Nandi; Ryan Vandrey; Denis G Antoine; Annie Umbricht; Angela S Guarda; Dean F Wong; Elise M Weerts
Journal:  Addict Biol       Date:  2021-05-24       Impact factor: 4.093

4.  Quantification of the Cannabinoid Type 1 Receptor Availability in the Mouse Brain.

Authors:  Isabelle Miederer; Viktoria Wiegand; Nicole Bausbacher; Petra Leukel; Stephan Maus; Manuela A Hoffmann; Beat Lutz; Mathias Schreckenberger
Journal:  Front Neuroanat       Date:  2020-11-20       Impact factor: 3.856

5.  The CB1R rs2023239 receptor gene variant significantly affects the reinforcing effects of nicotine, but not cue reactivity, in human smokers.

Authors:  Chidera C Chukwueke; William J Kowalczyk; Marie Gendy; Richard Taylor; Rachel F Tyndale; Bernard Le Foll; Stephen J Heishman
Journal:  Brain Behav       Date:  2020-12-25       Impact factor: 3.405

6.  Cannabinoid Receptor Type 1 in Parkinson's Disease: A Positron Emission Tomography Study with [18 F]FMPEP-d2.

Authors:  Riikka M Ajalin; Haidar Al-Abdulrasul; Jouni M Tuisku; Jussi E S Hirvonen; Tero Vahlberg; Salla Lahdenpohja; Juha O Rinne; Anna E Brück
Journal:  Mov Disord       Date:  2022-06-08       Impact factor: 9.698

Review 7.  Endocannabinoid system in psychotic and mood disorders, a review of human studies.

Authors:  Ranjini Garani; Jeremy J Watts; Romina Mizrahi
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2020-09-06       Impact factor: 5.067

Review 8.  Biomarkers of the Endocannabinoid System in Substance Use Disorders.

Authors:  Francisco Navarrete; María S García-Gutiérrez; Ani Gasparyan; Daniela Navarro; Francisco López-Picón; Álvaro Morcuende; Teresa Femenía; Jorge Manzanares
Journal:  Biomolecules       Date:  2022-03-03

9.  Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis.

Authors:  Guy Hindley; Katherine Beck; Faith Borgan; Cedric E Ginestet; Robert McCutcheon; Daniel Kleinloog; Suhas Ganesh; Rajiv Radhakrishnan; Deepak Cyril D'Souza; Oliver D Howes
Journal:  Lancet Psychiatry       Date:  2020-03-17       Impact factor: 77.056

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.